RZLT Rezolute, Inc.
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead cli…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
Sector Update: Healthcare Stocks Softer Late Afternoon Healthcare stocks were lower late Wednesday afternoon with the NYSE Healthcare Index and the State S | ||
Sector Update: Healthcare Stocks Decline in Afternoon Trading Healthcare stocks were lower Wednesday afternoon, with the NYSE Healthcare Index down 0.3% and the S | ||
 Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint Rezolute (NASDAQ:RZLT) said the FDA is continuing its review of additional Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism after the study failed to meet its primary endpoint, leaving the potential regulatory path unresolved and without a specific timeline for agency feedback. Key Investor TakeawaysThe FDA review remains ongoing as the agency evaluates whether there is a potential regulatory path forward for ersodetug in congenital hyperinsulinism. | ||